As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of 60 Degrees Pharmaceuticals, Inc. The largest reported stake is Knight Therapeutics Inc.'s, at 19.85%. 12 filings are on record since July 17, 2025 (Schedule 13G, July 29, 2026).
Sell to companies like 60 Degrees Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Lind Global Fund III LP · Sole voting: 191,571 · Shared voting: 0 · Sole dispositive: 191,571 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-05
- · Reporting person: Knight Therapeutics Inc. · Sole voting: 658,629 · Shared voting: 0 · Sole dispositive: 658,629 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-29
- · Reporting person: CVI Investments, Inc. · Sole voting: 0 · Shared voting: 197,911 · Sole dispositive: 0 · Shared dispositive: 197,911 · SCHEDULE 13G/A, 2026-05-15
- · Holder: Knight Therapeutics Inc. · Percent: 0% · SCHEDULE 13G/A
- · Reporting person: Mitchell P. Kopin · Sole voting: 0 · Shared voting: 263,158 · Sole dispositive: 0 · Shared dispositive: 263,158 · SCHEDULE 13G/A, 2026-05-13
60 Degrees Pharmaceuticals, Inc. has 12 Schedule 13D or 13G filings on record since 2025-07-17. 4 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Knight Therapeutics Inc. | 19.85% | 658,629 | SCHEDULE 13G, 2026-07-29 | 2026-07-22 |
| 9.1% | 263,158 | SCHEDULE 13G/A, 2026-05-13 | 2026-03-31 | |
| CVI Investments, Inc. | 7% | 197,911 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Lind Global Fund III LP | 5.45% | 191,571 | SCHEDULE 13G, 2026-08-05 | 2026-07-31 |
| Orca Capital AG | 4.9% | 166,229 | SCHEDULE 13G/A, 2025-07-17 | 2025-07-15 |
| Ayrton Capital LLC | 4.14% | 177,427 | SCHEDULE 13G/A, 2025-11-13 | 2025-09-30 |
Holding shares or following this stake? See who's behind 60 Degrees Pharmaceuticals, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on 60 Degrees Pharmaceuticals, Inc. and the records around it.
60 Degrees Pharmaceuticals, Inc. elsewhere on the record
- Leadership changes May 2026
- Who owns it
Companies that share a holder
- Lind Global Fund III LP also filed stake reports on 11 other companies: Dare Bioscience, Inc. (Aug 2026), DEFSEC Technologies Inc. (Aug 2026), Enveric Biosciences, Inc. (Aug 2026)
- Orca Capital AG also filed stake reports on 19 other companies: DarkIris Inc. (Oct 2026), Neo-Concept International Group Holdings Limited (Oct 2026), NFT Limited (Sep 2026)
- Ayrton Capital LLC also filed stake reports on 31 other companies: Bluejay Diagnostics, Inc. (Aug 2026), BTC Digital Ltd. (Aug 2026), DEFSEC Technologies Inc. (Aug 2026)
Watch 60 Degrees Pharmaceuticals, Inc.
Get an email when 60 Degrees Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on 60 Degrees Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on 60 Degrees Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on 60 Degrees Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Knight Therapeutics Inc. | 658,629 | 0 | 658,629 | 0 | SCHEDULE 13G, 2026-07-29 |
| Mitchell P. Kopin | 0 | 263,158 | 0 | 263,158 | SCHEDULE 13G/A, 2026-05-13 |
| Daniel B. Asher | 0 | 263,158 | 0 | 263,158 | SCHEDULE 13G/A, 2026-05-13 |
| Intracoastal Capital LLC | 0 | 263,158 | 0 | 263,158 | SCHEDULE 13G/A, 2026-05-13 |
| CVI Investments, Inc. | 0 | 197,911 | 0 | 197,911 | SCHEDULE 13G/A, 2026-05-15 |
| Heights Capital Management, Inc. | 0 | 197,911 | 0 | 197,911 | SCHEDULE 13G/A, 2026-05-15 |
| Lind Global Fund III LP | 191,571 | 0 | 191,571 | 0 | SCHEDULE 13G, 2026-08-05 |
| Lind Global Partners III LLC | 191,571 | 0 | 191,571 | 0 | SCHEDULE 13G, 2026-08-05 |
| Easton Jeff | 191,571 | 0 | 191,571 | 0 | SCHEDULE 13G, 2026-08-05 |
The latest filing identifies 60 Degrees Pharmaceuticals, Inc. by CUSIP 83006G500 and gives its principal executive office as 1025 Connecticut Avenue, NW Suite 1000, Washington D.C., DC 20036 (SCHEDULE 13G, 2026-08-05).
What the percentages are based on
19.85%. The above percentage is calculated based on 2,659,288 shares of common stock, par value $0.0001 per share, of the Issuer that are issued and outstanding as of May 15, 2026, as reported by the Issuer in its quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission on May 15, 2026.Knight Therapeutics Inc., SCHEDULE 13G, 2026-07-29
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-17 | Orca Capital AG | 9.9% | SCHEDULE 13G |
| 2025-07-17 | Orca Capital AG | 4.9% | SCHEDULE 13G/A |
| 2025-07-18 | Mitchell P. Kopin | 9.99% | SCHEDULE 13G |
| 2025-07-22 | CVI Investments, Inc. | 9.9% | SCHEDULE 13G |
| 2025-11-07 | Mitchell P. Kopin | 9.99% | SCHEDULE 13G/A |
| 2025-11-07 | CVI Investments, Inc. | 9.9% | SCHEDULE 13G/A |
| 2025-11-13 | Ayrton Capital LLC | 4.14% | SCHEDULE 13G/A |
| 2026-05-13 | Mitchell P. Kopin | 9.1% | SCHEDULE 13G/A |
| 2026-05-15 | Knight Therapeutics Inc. | 0% | SCHEDULE 13G/A |
| 2026-05-15 | CVI Investments, Inc. | 7% | SCHEDULE 13G/A |
| 2026-07-29 | Knight Therapeutics Inc. | 19.85% | SCHEDULE 13G |
| 2026-08-05 | Lind Global Fund III LP | 5.45% | SCHEDULE 13G |
Questions about who owns 60 Degrees Pharmaceuticals, Inc.
Who owns 60 Degrees Pharmaceuticals, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of 60 Degrees Pharmaceuticals, Inc.: Knight Therapeutics Inc. (19.85%, Schedule 13G, filed 2026-07-29), Mitchell P. Kopin (9.1%, Schedule 13G/A, filed 2026-05-13), CVI Investments, Inc. (7%, Schedule 13G/A, filed 2026-05-15) and Lind Global Fund III LP (5.45%, Schedule 13G, filed 2026-08-05).
Who are the largest shareholders of 60 Degrees Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of 60 Degrees Pharmaceuticals, Inc. on this page are Knight Therapeutics Inc. (19.85%), Mitchell P. Kopin (9.1%) and CVI Investments, Inc. (7%).
When did Knight Therapeutics Inc. buy into 60 Degrees Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Knight Therapeutics Inc. on this page is the Schedule 13G/A, filed 2026-05-15, reporting 0%; its latest, Schedule 13G filed 2026-07-29, reports 19.85%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for 60 Degrees Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 18, 2026 | Leadership change: Eric Francois appointed, Director | — | Leadership changes | Source |
| February 12, 2025 | Form D, private offering | $1.08M sold | Form D page | Source |
| February 11, 2025 | Form D, private offering | $1.04M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for 60 Degrees Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.